Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation.

Trial Profile

Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2012 Planned End Date changed from 1 Apr 2012 to 1 Nov 2012 as reported by University Hospital Medical Information Network - Japan.
    • 28 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 02 Mar 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top